I'm A Patient
I'm A Provider
Overview
If your macular degeneration is getting worse, the first step depends on how quickly it has changed. A sudden or rapid change in central vision, new distortion, a dark spot appearing, or a noticeable drop in vision over days rather than months warrants prompt contact with your eye care provider, as this can indicate conversion from dry to wet AMD, which needs urgent assessment.1
For gradual worsening of dry AMD over a longer period of time, it is usually recommended to make sure your monitoring is current, review whether your management plan reflects everything now available, and specifically ask whether your eye doctor offers MacuMira, a device-based therapy shown to improve visual function in qualifying individuals with dry AMD.
Urgent Changes vs. Gradual Progression
Dry AMD typically progresses slowly. Most patients experience a gradual reduction in central vision sharpness, with creeping difficulty reading small print, recognizing faces at a distance, or seeing in low-contrast conditions. This gradual pattern, while unwelcome, usually does not require an emergency response, though it warrants prompt attention at the next opportunity.1
A sudden change is different. If you experience sudden distortion of your central vision, including straight lines suddenly appearing wavy, a new gray or dark area, or a rapid drop in how clearly you see, seek prompt eye care attention. These symptoms can indicate the onset of wet AMD, in which abnormal blood vessels grow beneath the retina (the light-sensitive tissue at the back of the eye) and can cause rapid, severe vision loss if not treated promptly, often with anti-VEGF injections.1
If you notice any changes like these, contact your eye care provider the same day or go to an emergency eye care service. Do not wait for a routine appointment.
Between scheduled visits, daily self-monitoring with an Amsler grid, a simple grid pattern used to detect central vision changes, can help patients identify when it may be time to book an appointment with their eye doctor.
Reviewing your Current Management Plan
Monitoring
Retinal imaging with optical coherence tomography (OCT) is the standard tool for tracking dry AMD over time. If it has been more than 6 to 12 months since your last imaging, it’s a good idea to update your images, as your current management decisions may be based on an outdated picture of your disease status.
If you are not already on a structured monitoring schedule with defined review intervals, ask your provider to put one in place. Patients with intermediate or more advanced dry AMD are generally reviewed more frequently than those with early disease.
AREDS2 Supplements
AREDS2 supplementation, a combination of lutein, zeaxanthin, vitamin C, vitamin E, copper, and zinc, has been shown to reduce the risk of progression to advanced AMD in patients with intermediate dry AMD or advanced disease in one eye. If you have not discussed supplementation with your provider or if you started supplements without having your AMD stage confirmed, it may be worth revisiting.3
AREDS2 supplements address structural progression risk, not visual acuity or contrast sensitivity. Talk to your eye doctor before starting treatment, as not everyone is a good candidate for AREDS2 supplementation. For example, supplements containing beta-carotene are not recommended for current or former smokers. Confirm your eligibility and formulation choice with a clinician.3
Lifestyle Changes
Specific lifestyle factors can affect the progression of dry AMD, which is why eye doctors often include habit guidance in the conversation. If you smoke, stopping is the single most impactful lifestyle change you can make for AMD. Smokers face substantially higher rates of AMD progression than non-smokers.
A pattern rich in leafy greens, colourful vegetables and oily fish is also associated with lower AMD risk, though it should not replace regular monitoring through an eye care professional. UV-protective eyewear, blood pressure management, and regular physical activity are also relevant. These changes are low-risk and appropriate at every stage of dry AMD.4
MacuMira for Dry AMD
MacuMira is a device-based therapy authorized by Health Canada for the treatment of dry AMD. It is designed to improve visual acuity in patients who have already experienced some degree of loss.2
MacuMira delivers low-level electrical stimulation noninvasively to tissues near the eye, under the supervision of a licensed eye care professional. In its published randomized, sham-controlled clinical trial, the treatment group showed statistically significant improvement in both visual acuity and contrast sensitivity. The average gain was 8.2 letters on the ETDRS scale, with 48% of treated patients gaining 10 or more letters. Contrast sensitivity improved by an average of 0.24 log units. Zero device-related serious adverse events were recorded in the trial or in real-world use across more than 21,000 treatments in three countries.2
Eligibility is based on AMD stage and baseline visual acuity. MacuMira is not indicated for wet AMD. Patients with visual acuity better than 20/50 may experience a ceiling effect, which is why talking with an eye care professional about what to expect is an important part of the process. A clinical assessment is required to determine whether device-based therapy is appropriate.2
Talk to Your Provider
If your AMD management plan has not been updated in several years or if you have raised the question of newer options and been told that nothing has changed, it may be worth asking more directly.
You can ask your eye doctor if more options for dry AMD that have become available in the last few years. If the answer doesn’t cover device-based therapy to improve visual function, ask specifically about that.
If you feel your current provider is not offering a complete picture, seeking a second opinion from a retinal specialist or an optometry practice with a dedicated interest in AMD management is a legitimate step. AMD is a long-term condition, and your relationship with your eye care provider should include confidence that you are being offered current options.
When to Look for a Low Vision Specialist
For patients who have already experienced significant central vision loss, there are approaches worth raising with a provider. First, an assessment for MacuMira can help determine whether any functional improvement is achievable. Alongside that, a referral to a low vision specialist may help address the practical impact of current vision loss on daily life.1
Low vision rehabilitation helps patients maximize their remaining vision through magnification devices, adaptive lighting, contrast enhancement strategies, and practical training for everyday tasks like reading, cooking, and navigating safely. It does not treat dry AMD but addresses what vision loss has already cost in terms of independence and daily function. Patients who feel their vision is limiting what they can do independently should ask their provider for a referral.1
These approaches are not mutually exclusive. A patient can be assessed for device-based therapy while also engaging with low vision services, depending on the severity of their current vision loss and their individual goals.
Questions to Ask at Your Next Appointment
- Has my AMD stage changed since my last assessment, and what does the current imaging show?1
- Am I on the right monitoring schedule for my level of disease?1
- Should I be taking AREDS2 supplements and is the formulation I am using appropriate?3
- Is device-based therapy to improve visual function something I should consider, given where my AMD is now?2
- Are there any options for managing dry AMD that have become available since I was last assessed?
- What lifestyle changes would have the most impact for me at this stage?
- Should I be referred to a low vision specialist given the functional impact my AMD is currently having?
Conclusion
If your macular degeneration is getting worse, the response depends on whether the change is sudden or gradual. Sudden changes require urgent review to rule out wet AMD. Gradual worsening of dry AMD calls for an updated clinical assessment, a review of all current management options and a direct conversation about whether anything has changed since you were last assessed. Health Canada has authorized MacuMira to improve visual function in dry AMD patients, supported by a published clinical trial and more than 21,000 real-world treatments. Patients whose plans have not been reviewed recently should ask specifically what is now available for their stage of disease.
Disclaimer
This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. If you experience a sudden change in your vision, contact an eye care professional promptly. For ongoing management of dry AMD, speak with a qualified eye care provider about which options are appropriate for your specific condition and stage of disease.
Glossary
Dry AMD (dry age-related macular degeneration): A progressive retinal condition in which the macula deteriorates gradually over time. The most common form of AMD. Distinct from wet AMD in cause and treatment.
Wet AMD: A form of AMD involving abnormal blood vessel growth beneath the retina. Can cause rapid vision loss and requires different treatment, anti-VEGF injections, from dry AMD. Microcurrent therapy devices are not indicated for wet AMD.
Anti-VEGF injections: Medications injected into the eye to block abnormal blood vessel growth in wet AMD. Not used for dry AMD.
MacuMira: An approved medical device indicated to improve visual function in patients with dry AMD, delivered via low-level electrical stimulation in a clinical setting under the supervision of an eye care professional. Not indicated for wet AMD.
AREDS2 formula: A nutritional supplement combination including lutein, zeaxanthin, vitamin C, vitamin E and zinc. Reduces progression risk to advanced AMD in eligible patients. Does not improve visual acuity or contrast sensitivity.
Amsler grid: A simple grid-based self-monitoring tool used at home to detect changes in central vision between clinical appointments. Changes such as waviness, distortion or missing areas should prompt immediate contact with an eye care provider.
Optical coherence tomography (OCT): A non-invasive retinal imaging technology that produces detailed cross-sectional images of the macula. Standard for monitoring dry AMD progression.
ETDRS scale: The Early Treatment Diabetic Retinopathy Study visual acuity scale, scored letter by letter. The standard outcome measure in AMD clinical trials.
Contrast sensitivity: The ability to distinguish objects from their background at varying contrast levels. Frequently affected in dry AMD independently of high-contrast visual acuity.
Low vision rehabilitation: Specialist services that help patients with significant vision loss maintain daily independence through magnification, adaptive strategies and practical training.
Ceiling effect: In clinical measurement, the limited room for improvement when a patient’s baseline function is already near the upper end of the measurement range.
References
1. Age-Related Macular Degeneration. National Eye Institute, National Institutes of Health. Last reviewed November 2023. Accessed June 2026. https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration.
2. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Parkinson KM, Sayre EC, Tobe SW. International Journal of Retina and Vitreous. Published May 2023. Accessed June 2026. https://macumira.com/wp-content/uploads/2025/07/MacuMira-Clinical-Trial.pdf.
3. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. AREDS2 Research Group. JAMA. Published May 15, 2013. Accessed June 2026. https://jamanetwork.com/journals/jama/fullarticle/1684847.
4. Understanding Macular Degeneration. American Academy of Ophthalmology. Published November 2025. Accessed June 2026. https://www.aao.org/eye-health/diseases/amd-macular-degeneration.
5. Age-Related Macular Degeneration (AMD). Canadian Ophthalmological Society. Date not listed. Accessed June 2026. https://www.seethepossibilities.ca/eye-health/age-related-macular-degeneration/.
